Vaccination of renal cell cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-α (IFN-α): A phase 2 trial

Journal of Immunotherapy

Volumn 32, Issue 7, 2009, Pages 765-772

  Amato, Robert J ^a   Shingler, William ^b   Goonewardena, Madusha ^b   De Belin, Jackie ^b   Naylor, Stuart ^b   Jac, Jaroslaw ^c   Willis, James ^c   Saxena, Somyata ^c   Hernandez Mcclain, Joan ^a   Harrop, Richard ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Clinical immunology: cancer vaccines; Genitourinary cancers: other; Laboratory correlates; Phase 1 3 trials

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIBODY; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GAMMA INTERFERON; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; MG 98; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ONCOFETAL ANTIGEN; RETINOIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TUMOR ANTIGEN; TUMOR ANTIGEN 5T4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL METASTASIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBODY BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SOFT TISSUE METASTASIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANEMIA; ANTIBODIES, VIRAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; KIDNEY NEOPLASMS; LYMPHOPENIA; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS;

EID: 68449100522     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ace876     Document Type: Article

References (17)

1. Cancer Facts and Figures 2006. American Cancer Society, 2006.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Hole N, Stern PL. A 72 kD trophoblast glycoprotein denned by a monoclonal antibody. Br J Cancer. 1988;57:239-246.
4. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohisto-logical distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
5. Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902.
6. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005;93:670-677.
7. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12:3416-3424.
8. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13:4487-4494.
9. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax®): a phase II trial. J Immunotherapy. 2008;31:577-585.
10. Amato R, Shingler W, Harrop R, et al. Vaccination of renal cancer patients with modified vaccinia ankara delivering the tumor antigen 5t4 (TroVax) in combination with IL-2: a phase II trial. Clinical Cancer Research. 2008;14:7504-7510.
11. Van Herpen CM, Jansen RL, Kruit WH et al. Immunochemo-therapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer. 2000;82:772-776.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
13. NCI Common Toxicity Criteria (CTC) Version 3.0. http://ctep.cancer.gov/ reporting/ctc.html
14. Harrop R, Ryan MG, Myers KA, et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother. 2006;55:1081-1090.
15. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528.
16. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376-2381.
17. Hawkins R, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cancer with modified Vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside Interferon-a. J Immunother. 2009;32:424-429.